Response to “Levosimendan’s ability on veno-arterial extracorporeal membrane oxygenation weaning: Evidence says yes!”

Abstract

Get full access to this article

View all access options for this article.

References

Hau

Fong

K-M

S-Y

. Levosimendan’s effect on venoarterial extracorporeal membrane oxygenation weaning. Int J Artif Organs 2022; 45: 571–579.

Jacky

Rudiger

Kruger

, et al. Comparison of Levosimendan and Milrinone for ECLS weaning in patients after cardiac surgery-a retrospective before-and-after study. J Cardiothorac Vasc Anesth 2018; 32: 2112–2119.

Guilherme

Jacquet-Lagreze

Pozzi

, et al. Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis. Crit Care 2020; 24: 442.

Alonso-Fernandez-Gatta

Merchan-Gomez

Gonzalez-Cebrian

, et al. Levosimendan in veno-arterial extracorporeal membrane oxygenator supported patients: impact on the success of weaning and survival. Artif Organs 2021; 45: 717–725.

Vally

Ferdynus

Persichini

, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care 2019; 9: 24.

Distelmaier

Roth

Schrutka

, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth 2016; 117: 52–58.